Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096880011> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W3096880011 endingPage "e11" @default.
- W3096880011 startingPage "e9" @default.
- W3096880011 abstract "Sodium–glucose cotransporter 2 (SGLT2) inhibitors are second- to third-line antidiabetes drugs that have been shown to have cardiovascular benefits. However, in premarketing trials of the SGLT2 inhibitor dapagliflozin, there were numerical imbalances in breast cancer events compared with placebo; all occurred within 1 year of randomization (rate ratio 2.47, 95% CI 0.64–14.10) (1). In contrast, no imbalances were observed in subsequent large cardiovascular outcome trials of dapagliflozin and other SGLT2 inhibitors (2–4).While the discrepant findings between the pre- and postmarketing trials could be due to chance, one hypothesis is that the early breast cancer imbalances are the result of an accelerated tumor-promoting effect of SGLT2 inhibitors. However, this is unlikely, given that sodium–glucose cotransporter proteins are not expressed in mammary tissue, and animal studies have failed to demonstrate that SGLT2 inhibitors have any neoplastic activity (5). Another hypothesis relates to the weight-lowering effects of SGLT2 inhibitors, which could facilitate the detection of existing breast lumps, thus leading to a transient overdetection of breast cancer. To date, this possible association has not been investigated in the real-world setting.We conducted a population-based cohort study using the U.K. Clinical Practice Research Datalink (CPRD) (protocol: 19_272). We identified all female patients newly treated with either an SGLT2 inhibitor (dapagliflozin, …" @default.
- W3096880011 created "2020-11-09" @default.
- W3096880011 creator A5002024158 @default.
- W3096880011 creator A5012678671 @default.
- W3096880011 creator A5016406653 @default.
- W3096880011 creator A5028735116 @default.
- W3096880011 creator A5083123077 @default.
- W3096880011 date "2020-11-06" @default.
- W3096880011 modified "2023-10-16" @default.
- W3096880011 title "Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes" @default.
- W3096880011 cites W1974463975 @default.
- W3096880011 cites W2146264128 @default.
- W3096880011 cites W2626446274 @default.
- W3096880011 cites W2767934199 @default.
- W3096880011 cites W2900413769 @default.
- W3096880011 doi "https://doi.org/10.2337/dc20-1073" @default.
- W3096880011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33158946" @default.
- W3096880011 hasPublicationYear "2020" @default.
- W3096880011 type Work @default.
- W3096880011 sameAs 3096880011 @default.
- W3096880011 citedByCount "5" @default.
- W3096880011 countsByYear W30968800112021 @default.
- W3096880011 countsByYear W30968800112022 @default.
- W3096880011 countsByYear W30968800112023 @default.
- W3096880011 crossrefType "journal-article" @default.
- W3096880011 hasAuthorship W3096880011A5002024158 @default.
- W3096880011 hasAuthorship W3096880011A5012678671 @default.
- W3096880011 hasAuthorship W3096880011A5016406653 @default.
- W3096880011 hasAuthorship W3096880011A5028735116 @default.
- W3096880011 hasAuthorship W3096880011A5083123077 @default.
- W3096880011 hasBestOaLocation W30968800111 @default.
- W3096880011 hasConcept C121332964 @default.
- W3096880011 hasConcept C121608353 @default.
- W3096880011 hasConcept C126322002 @default.
- W3096880011 hasConcept C134018914 @default.
- W3096880011 hasConcept C143998085 @default.
- W3096880011 hasConcept C178790620 @default.
- W3096880011 hasConcept C185592680 @default.
- W3096880011 hasConcept C188053792 @default.
- W3096880011 hasConcept C2777180221 @default.
- W3096880011 hasConcept C530470458 @default.
- W3096880011 hasConcept C537181965 @default.
- W3096880011 hasConcept C555293320 @default.
- W3096880011 hasConcept C61797465 @default.
- W3096880011 hasConcept C62520636 @default.
- W3096880011 hasConcept C71924100 @default.
- W3096880011 hasConceptScore W3096880011C121332964 @default.
- W3096880011 hasConceptScore W3096880011C121608353 @default.
- W3096880011 hasConceptScore W3096880011C126322002 @default.
- W3096880011 hasConceptScore W3096880011C134018914 @default.
- W3096880011 hasConceptScore W3096880011C143998085 @default.
- W3096880011 hasConceptScore W3096880011C178790620 @default.
- W3096880011 hasConceptScore W3096880011C185592680 @default.
- W3096880011 hasConceptScore W3096880011C188053792 @default.
- W3096880011 hasConceptScore W3096880011C2777180221 @default.
- W3096880011 hasConceptScore W3096880011C530470458 @default.
- W3096880011 hasConceptScore W3096880011C537181965 @default.
- W3096880011 hasConceptScore W3096880011C555293320 @default.
- W3096880011 hasConceptScore W3096880011C61797465 @default.
- W3096880011 hasConceptScore W3096880011C62520636 @default.
- W3096880011 hasConceptScore W3096880011C71924100 @default.
- W3096880011 hasFunder F4320334506 @default.
- W3096880011 hasIssue "1" @default.
- W3096880011 hasLocation W30968800111 @default.
- W3096880011 hasOpenAccess W3096880011 @default.
- W3096880011 hasPrimaryLocation W30968800111 @default.
- W3096880011 hasRelatedWork W1966504330 @default.
- W3096880011 hasRelatedWork W1979139803 @default.
- W3096880011 hasRelatedWork W2006202112 @default.
- W3096880011 hasRelatedWork W2013015015 @default.
- W3096880011 hasRelatedWork W2037631372 @default.
- W3096880011 hasRelatedWork W2040058909 @default.
- W3096880011 hasRelatedWork W2132898409 @default.
- W3096880011 hasRelatedWork W2138029694 @default.
- W3096880011 hasRelatedWork W2224319365 @default.
- W3096880011 hasRelatedWork W2748952813 @default.
- W3096880011 hasVolume "44" @default.
- W3096880011 isParatext "false" @default.
- W3096880011 isRetracted "false" @default.
- W3096880011 magId "3096880011" @default.
- W3096880011 workType "article" @default.